Cigna earnings beat by $0.04, revenue topped estimates
GUILFORD, Conn. - Hyperfine, Inc. (NASDAQ:HYPR) has appointed Rafael O’Halloran, PhD, as Vice President of Technology and Rob Fasciano, PhD, as Chief Regulatory and Quality Officer, according to a company press release.
The appointments come as the company continues to commercialize its Swoop portable MRI system, which is FDA-cleared for brain imaging. Both executives were involved in the development of the recently FDA-cleared Optive AI software and next-generation Swoop scanner.
Dr. Fasciano brings over 25 years of experience in regulatory affairs, quality systems, and R&D from companies including Abiomed, Johnson & Johnson, and Orchestra BioMed. He holds a PhD from Johns Hopkins University and an MBA from Purdue University.
Dr. O’Halloran has more than two decades of experience in MRI physics and led the development of Hyperfine’s AI-driven image pipeline. Previously, he served as an Assistant Professor of Radiology at Mount Sinai School of Medicine and was a research associate at Stanford University.
"Technology innovation is at the core of our mission and central to accelerating global adoption of the Swoop system," said Maria Sainz, President and CEO of Hyperfine, in the statement.
Hyperfine describes its Swoop system as the first FDA-cleared, portable, ultra-low-field magnetic resonance brain imaging system designed for use at multiple points of care. The company was founded by Dr. Jonathan Rothberg in a technology incubator called 4Catalyzer.
The appointments are expected to support the company’s global rollout of its new technology and development of future software enhancements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.